Israeli biotech Enlivex has developed a treatment called ApoCell that triggers a response from the immune system to reduce adverse reactions during bone marrow transplants. It prevents Graft vs Host Disease (GVHD), which affects around 70% of transplant patients. http://unitedwithisrael.org/enlivex-innovation-leads-to-effective-new-cancer-treatment/ … Continue reading →